The interaction between a common gene variant and gut microbes may trigger chronic inflammation in ulcerative colitis, new ...

Ulcerative colitis is a form of inflammatory bowel disease (IBD) that causes inflammation and open sores (ulcers) in the ...

Ulcerative colitis, a chronic inflammatory bowel disease, presents treatment challenges due to its variable symptoms and unpredictable flare-ups. The global market is set to grow, driven by biologic ...

Abivax has shared positive top-line results from two late-stage studies of its investigational oral miR-124 enhancer in adults with moderately to severely active ulcerative colitis (UC).

Among the new options is filgotinib, an oral medication that has become the most-used first-line therapy since 2021. Unlike ...

American depositary receipts of French biotechnology firm Abivax rose more than sixfold premarket after a drug candidate for bowel condition ulcerative colitis showed promise in a late-stage clinical ...

Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 02:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the ...

Marisa Marinelli was told her colon might need to be removed to heal her ulcerative colitis. At 29, she was diagnosed with ...

A low-emulsifier-containing diet led to a threefold increased likelihood of improvement in symptoms of Crohn’s disease ...

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares ...

In a key advance for regenerative medicine and gut health, scientists from Duke-NUS Medical School and Nanyang Technological ...

ACROBiosystems is breaking the chain of chronic suffering and safeguarding intestinal health. Learn how in this article.